Zymeworks (ZYME) Q1 2026 earnings summary

Executive summary

• Achieved key regulatory milestones for zanidatamab, including FDA Priority Review with a PDUFA date of August 25, 2026, and sBLA acceptance in China, positioning for significant milestone payments and long-term royalties.

• Presented potentially practice-changing Phase 3 data for zanidatamab in 1L HER2+ GEA, with ongoing royalty revenue and further regulatory submissions expected.

• Advanced ADC pipeline with promising preclinical and clinical data, notably for pan-RAS ADCs and ZW191, supporting R&D scalability and innovation.

• Strengthened leadership team with strategic hires and experienced executives to enhance capital allocation and execution capabilities.

Financial highlights

• Q1 2026 revenue was $2.4 million, down from $27.1 million in Q1 2025, mainly due to non-recurring milestone payments in the prior year.

• R&D expenses were $34.5 million, slightly down from $35.7 million year-over-year; G&A expenses decreased to $15.1 million from $17.0 million.

• Net loss widened to $44.2 million from $22.6 million year-over-year, primarily due to lower revenue.

• Cash, cash equivalents, and marketable securities totaled $403.8 million as of March 31, 2026, up from $270.6 million at year-end 2025.

Outlook and guidance

• Anticipates $440 million in regulatory milestone payments upon potential approvals in major markets, expected to fund operations beyond 2028.

• Reiterated guidance for approximately $300 million in aggregate adjusted gross operating expenditures (non-GAAP) over three years ending December 31, 2028.

• Expects continued growth in royalty revenue as commercial sales of Ziihera increase.

• IND for ZW1528 now guided for 2027, with non-U.S. regulatory submission planned for 2026.